InflaRx (IFRX) Total Liabilities (2016 - 2026)
InflaRx (IFRX) posted Total Liabilities of $14.0 million for Q1 2026, down 11.65% sequentially from $15.9 million in Q4 2025, and down 19.23% YoY from $17.4 million in Q1 2025.
InflaRx (IFRX) Total Liabilities (2016 - 2026) Analysis & Trends
InflaRx has reported Total Liabilities for 11 years, with the latest figure at $14.0 million in Q1 2026.
- Quarterly Total Liabilities fell 19.23% year-over-year to $14.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.0 million (down 19.23% YoY) and the FY2025 annual result came in at $15.4 million, down 2.35% from the prior year.
- Total Liabilities fell to $14.0 million in Q1 2026 per IFRX's latest filing, from $15.9 million in the prior quarter.
- Over five years, Total Liabilities peaked at $23.1 million in Q3 2025 and troughed at $8.3 million in Q1 2023.
- A 5-year average of $15.1 million and a median of $14.3 million in 2022 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2023: Total Liabilities surged 121.11% in 2022, then sank 62.95% in 2023.
- Over 5 years, Total Liabilities stood at $14.3 million in 2022, then surged by 32.3% to $19.0 million in 2023, then dropped by 17.72% to $15.6 million in 2024, then increased by 1.9% to $15.9 million in 2025, then declined by 11.65% to $14.0 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $14.0 million, $15.9 million, and $23.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | 24.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.05 Mn |
| Dec 31, 2025 | 15.90 Mn |
| Sep 30, 2025 | 23.14 Mn |
| Jun 30, 2025 | 18.56 Mn |
| Mar 31, 2025 | 17.39 Mn |
| Dec 31, 2024 | 15.60 Mn |
| Sep 30, 2024 | 15.82 Mn |
| Jun 30, 2024 | 11.72 Mn |
| Mar 31, 2024 | 13.40 Mn |
| Dec 31, 2023 | 18.97 Mn |
| Sep 30, 2023 | 12.51 Mn |
| Jun 30, 2023 | 9.06 Mn |
| Mar 31, 2023 | 8.30 Mn |
| Dec 31, 2022 | 14.33 Mn |
| Sep 30, 2022 | 11.77 Mn |
| Jun 30, 2022 | 13.34 Mn |
| Mar 31, 2022 | 22.40 Mn |
| Dec 31, 2021 | 22.72 Mn |
| Sep 30, 2021 | 16.68 Mn |
| Jun 30, 2021 | 13.75 Mn |